Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02NMR
|
|||
| Drug Name |
SFX-01
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 2 | [1] | |
| Subarachnoid hemorrhage [ICD-11: 8B01] | Phase 2 | [2] | ||
| Company |
Evgen Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target Info | Activator | [3] |
| KEGG Pathway | Protein processing in endoplasmic reticulum | |||
| NetPath Pathway | IL5 Signaling Pathway | |||
| WikiPathways | Oxidative Stress | |||
| Transcriptional activation by NRF2 | ||||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Aryl Hydrocarbon Receptor Pathway | ||||
| Mesodermal Commitment Pathway | ||||
| Aryl Hydrocarbon Receptor | ||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | ||||
| Arylhydrocarbon receptor (AhR) signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02970682) SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer (STEM). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02614742) SFX-01 After Subarachnoid Haemorrhage (SAS). U.S. National Institutes of Health. | |||
| REF 3 | Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.